Moteur de recherche d’entreprises européennes
Financement de l’UE (6 069 750 €) : PRECISION MEDICINE PLATFORM IN NEURODEGENERATIVE DISEASE Hor01/05/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
PRECISION MEDICINE PLATFORM IN NEURODEGENERATIVE DISEASE
Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Comorbidities with these conditions are frequent and a major obstacle to optimal diagnosis and management. Recent advances in diagnostic technologies and the advent of disease-modifying therapies (DMT) for Alzheimer’s disease (AD), the most common aetiology of dementia, heralds the beginning of precision medicine in this disease area. PROMINENT will develop a digital platform for precision medicine that will remove barriers that currently exists for leveraging these technological advancements in the routine care of patients with neurodegenerative disorders and co-morbidities. The platform gives clinicians access to prediction models leveraging multimodal diagnostic data automatically derived from multiple sources (imaging repositories, medical records, mobile devices), helping them choose optimal care pathways and improving diagnostic precision. It will provide personalized, relevant and meaningful information on diagnosis and prognosis in a format understandable by patients and care partners. Further, it will support the introduction of new health technologies such as DMT for AD, by ensuring adherence to appropriate use guidelines and facilitating the prospective collection of data on real-world usage, safety and effectiveness. The expected impact of the project is to increase diagnostic accuracy and optimized use of existing and new treatment options. It will empower patients and caregivers by engaging them in more person-centric health care decisions, leading to improved adherence and patient experience. Ultimately this is expected to lead to cost-effective care, improved health outcomes and quality of life.
| Alzheimer Europe | 398 750 € |
| Bioarctic AB | 0,00 € |
| CHU Hopitaux de Bordeaux | 173 375 € |
| COMBINOSTICS Oy | 0,00 € |
| COMBINOSTICS US Inc. | 0,00 € |
| DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN e. V. | 26 250 € |
| Fundacio Barcelonabeta Brain Research Center | 435 875 € |
| IHE, Institutet FOR Halso- och Sjukvardsekonomi AB | 357 250 € |
| ITA-SUOMEN YLIOPISTO | 372 125 € |
| Karolinska Institutet | 1 811 375 € |
| KLINIKUM DER UNIVERSITAET ZU KOELN | 558 375 € |
| Oslo Universitetssykehus HF | 157 500 € |
| Region Hovedstaden | 157 500 € |
| Region Stockholm | 462 125 € |
| STICHTING AMSTERDAM UMC | 302 125 € |
| Stiftelsen Fingers Brain Health Institute | 0,00 € |
| Synapse Research Management Partners SL | 555 000 € |
| Univerzitetni Klinicni Center Ljubljana | 302 125 € |
https://cordis.europa.eu/project/id/101112145
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
